Q1 results for CRH Medical, Exact Sciences & more

Here's a snapshot of first-quarter financial results for ASC-relevant gastroenterology and supply companies:

CRH Medical posted revenues of $29.1 million for the first quarter of 2019.

Exact Sciences posted first-quarter 2019 revenues of $162 million, a 79 percent year-over-year increase.

For the first quarter, Pacira BioSciences reported record sales of Exparel, a non-opioid pain management drug that became eligible for separate Medicare reimbursement in ASCs as of Jan. 1.

Specialty biopharmaceutical company EyePoint Pharmaceuticals reported $2 million in revenue for the first quarter of 2019, up from $928,000 year over year.

More articles on gastroenterology:
2 Texas clinicians unintentionally compromise patient information — 6 insights
AGA joins 'Let My Doctor Decide' to fight step therapy
Motus readies for commercial launch of Pure-Vu, posts $5.2M net loss for Q1 — 3 insights

© Copyright ASC COMMUNICATIONS 2019. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.

 

Top 40 Articles from the Past 6 Months